Sprout Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2011-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://addyi.com
Clinical Trials
13
Trial Phases
2 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
- Conditions
- Sexual Dysfunctions, Psychological
- Interventions
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- Sprout Pharmaceuticals, Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01188603
- Locations
- 🇺🇸
511.146.01003 Boehringer Ingelheim Investigational Site, Orlando, Florida, United States
🇺🇸511.146.01005 Boehringer Ingelheim Investigational Site, Wichita, Kansas, United States
🇺🇸511.146.01001 Boehringer Ingelheim Investigational Site, Kalamazoo, Michigan, United States
A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder
- First Posted Date
- 2010-04-14
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- Sprout Pharmaceuticals, Inc
- Target Recruit Count
- 596
- Registration Number
- NCT01103362
- Locations
- 🇺🇸
511.133.01074 Boehringer Ingelheim Investigational Site, Birmingham, Alabama, United States
🇺🇸511.133.01141 Boehringer Ingelheim Investigational Site, Birmingham, Alabama, United States
🇺🇸511.133.01046 Boehringer Ingelheim Investigational Site, Huntsville, Alabama, United States
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America
- Conditions
- Sexual Dysfunctions, Psychological
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-01-28
- Last Posted Date
- 2014-06-17
- Lead Sponsor
- Sprout Pharmaceuticals, Inc
- Target Recruit Count
- 748
- Registration Number
- NCT01057901
- Locations
- 🇺🇸
511.156.01059 Boehringer Ingelheim Investigational Site, Birmingham, Alabama, United States
🇺🇸511.156.01084 Boehringer Ingelheim Investigational Site, Tucson, Arizona, United States
🇺🇸511.156.01053 Boehringer Ingelheim Investigational Site, Tuscon, Arizona, United States
12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress
- Conditions
- DepressionSexual Dysfunctions, Psychological
- Interventions
- First Posted Date
- 2009-12-29
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Sprout Pharmaceuticals, Inc
- Target Recruit Count
- 111
- Registration Number
- NCT01040208
- Locations
- 🇺🇸
Clinical Innovations, Riverside, California, United States
🇺🇸Mood & Anxiety Research, Fresno, California, United States
🇺🇸Synergy Clinical Research Center, National City, California, United States
Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
- Conditions
- Sexual Dysfunctions, Psychological
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Sprout Pharmaceuticals, Inc
- Target Recruit Count
- 1090
- Registration Number
- NCT00996164
- Locations
- 🇺🇸
511.147.01074 Boehringer Ingelheim Investigational Site, Birmingham, Alabama, United States
🇺🇸511.147.01046 Boehringer Ingelheim Investigational Site, Huntsville, Alabama, United States
🇺🇸511.147.01042 Boehringer Ingelheim Investigational Site, Mobile, Alabama, United States
- Prev
- 1
- 2
- 3
- Next